Larnivudine-high dose interferon combination therapy in chronic hepatitis B patients co-infected with the hepatitis D virus

Wolters, Lmm; Nunen, A.B. van; Vossen, A.C.T.M.; Neisters, Hubert G. M.; Man, Robert A. de

doi:10.1097/00042737-199912000-00212

Search citation statements

Order By: Relevance

Paper Sections

Select...

Lamivudine Treatment1

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One would expect that administering lamivudine to individuals with chronic HBV and HDV would also reduce HDV levels. However, studies have shown that administering lamivudine has no significant effect on the levels of HDV RNA in infected patients [9,11,23,10]. Even after months of treatment, HDV viral production and liver damage (i.e.…”

Section: Lamivudine Treatmentmentioning

confidence: 99%

Mathematical models of the interrelated dynamics of hepatitis D and B

Packer

Forde

Hews

et al. 2014

Mathematical Biosciences

View full text Add to dashboard Cite

Section: Lamivudine Treatmentmentioning

confidence: 99%

Mathematical models of the interrelated dynamics of hepatitis D and B

Packer

Forde

Hews

et al. 2014

Mathematical Biosciences

View full text Add to dashboard Cite

“…LAM was found to be ineffective in treating chronic HDV infections when used alone or in combination with standard interferon-a (Niro et al, 2005;Lau et al, 1999;Yurdaydin et al, 2008;Wolters et al, 2000). The Hep-Net/ International Delta Hepatitis Intervention Trial (HIDIT)-1 involved patients with compensated chronic HDV infection and found that combination therapy with PEGylated interferon and adefovir for 48 weeks had no advantage over PEGylated interferon mono-therapy in reducing serum levels of HDV RNA and HBV DNA and that adefovir monotherapy was ineffective (Wedemeyer et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?

Babiker

Hogan

Ustianowski

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Infection with hepatitis delta virus (HDV) always occurs in association with hepatitis B virus (HBV) and is a cause of significant morbidity and mortality. We present a case of severe acute HDV infection superimposed on a previously unrecognized HBV infection, in which an interferonsparing antiviral therapy consisting of tenofovir disoproxil fumarate (TDF) and lamivudine was initiated and subsequently maintained. Evidence of successful suppression of HDV ribonucleic acid (RNA) was obtained after 65 weeks of TDF-based treatment. This was mirrored by a significant reduction in the levels of HBV DNA and HBV surface antigen. HDV RNA subsequently rebounded after our patient stopped antiviral therapy of his own accord. Interferon-sparing TDFbased antiviral therapy was safe and effective in achieving HDV RNA suppression in acute HDV superinfection. Further research into the utility of interferon-sparing TDF-based regimes in the treatment of acute HDV infection is needed.

show abstract

Larnivudine-high dose interferon combination therapy in chronic hepatitis B patients co-infected with the hepatitis D virus

Cited by 2 publications

References 0 publications

Mathematical models of the interrelated dynamics of hepatitis D and B

Mathematical models of the interrelated dynamics of hepatitis D and B

Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection?

Contact Info

Product

Resources

About